Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-31

Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial update on long-term safety, tolerability, and efficacy of bimekizumab in adults with chronic plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Chronic Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-31